Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Mercier
Cédric
C
Dahan
Laetitia
L
Ouafik
L'houcine
L
André
Nicolas
N
Ciccolini
Joseph
J
D000225:Adenine; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism*; D015986:Confounding Factors, Epidemiologic; D003564:Cytidine Deaminase / Q000235:genetics*; D003596:Cytosine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide; D012107:Research Design; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D003596:Cytosine; D003564:Cytidine Deaminase; D000225:Adenine; D000093542:Gemcitabine